Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

Platinum 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3Taxes 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Carboplatin 2sargramostim 1pembrolizumab 1dehydroftorafur 1X-Rays 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiation 1Polymerase Chain Reaction 1Pilocarpine 1Paclitaxel 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Gene Expression Profiling 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Laryngeal Neoplasms × Radiotherapy, Image-Guided × Clear all
NCT06084845 2024-07-25

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡